Cargando…
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
BACKGROUND: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk of recurrence. Current guidelines recommend trastuzumab and chemotherapy for most HER-2-positive patients. However, the majority of patients does not recur and might thus be overtreated...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008599/ https://www.ncbi.nlm.nih.gov/pubmed/21081926 http://dx.doi.org/10.1038/sj.bjc.6605916 |